Literature DB >> 29117940

ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1.

Nikhil Tyagi1, Sachin K Deshmukh1, Sanjeev K Srivastava1,2, Shafquat Azim1, Aamir Ahmad1, Ahmed Al-Ghadhban1, Ajay P Singh1,3, James E Carter4, Bin Wang5, Seema Singh6,3.   

Abstract

The ETS family transcription factor ETV4 is aberrantly expressed in a variety of human tumors and plays an important role in carcinogenesis through upregulation of relevant target gene expression. Here, it is demonstrated that ETV4 is overexpressed in pancreatic cancer tissues as compared with the normal pancreas, and is associated with enhanced growth and rapid cell-cycle progression of pancreatic cancer cells. ETV4 expression was silenced through stable expression of a specific short hairpin RNA (shRNA) in two pancreatic cancer cell lines (ASPC1 and Colo357), while it was ectopically expressed in BXPC3 cells. Silencing of ETV4 in ASPC1 and Colo357 cells reduced the growth by 55.3% and 38.9%, respectively, while forced expression of ETV4 in BXPC3 cells increased the growth by 46.8% in comparison with respective control cells. Furthermore, ETV4-induced cell growth was facilitated by rapid transition of cells from G1- to S-phase of the cell cycle. Mechanistic studies revealed that ETV4 directly regulates the expression of Cyclin D1 CCND1, a protein crucial for cell-cycle progression from G1- to S-phase. These effects on the growth and cell cycle were reversed by the forced expression of Cyclin D1 in ETV4-silenced pancreatic cancer cells. Altogether, these data provide the first experimental evidence for a functional role of ETV4 in pancreatic cancer growth and cell-cycle progression.Implications: The functional and mechanistic data presented here regarding ETV4 in pancreatic cancer growth and cell-cycle progression suggest that ETV4 could serve as a potential biomarker and novel target for pancreatic cancer therapy. Mol Cancer Res; 16(2); 187-96. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29117940      PMCID: PMC5805611          DOI: 10.1158/1541-7786.MCR-17-0219

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  52 in total

1.  PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.

Authors:  Martin Wartenberg; Irene Centeno; Stefan Haemmig; Erik Vassella; Inti Zlobec; José A Galván; Maja Neuenschwander; Cornelia Schlup; Beat Gloor; Alessandro Lugli; Aurel Perren; Eva Karamitopoulou
Journal:  Eur J Cancer       Date:  2016-07-29       Impact factor: 9.162

2.  Expression patterns of the Ets transcription factors from the PEA3 group during early stages of mouse development.

Authors:  A Chotteau-Lelievre; P Dolle; V Peronne; L Coutte; Y de Launoit; X Desbiens
Journal:  Mech Dev       Date:  2001-10       Impact factor: 1.882

3.  ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion.

Authors:  Alan C Moss; Garrett Lawlor; David Murray; Dónal Tighe; Stephen F Madden; Anne-Marie Mulligan; Conor O Keane; Hugh R Brady; Peter P Doran; Padraic MacMathuna
Journal:  Biochem Biophys Res Commun       Date:  2006-04-27       Impact factor: 3.575

4.  PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma.

Authors:  R Keld; B Guo; P Downey; R Cummins; C Gulmann; Y S Ang; A D Sharrocks
Journal:  Br J Cancer       Date:  2011-06-14       Impact factor: 7.640

5.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

6.  PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas.

Authors:  M S Trimble; J H Xin; C T Guy; W J Muller; J A Hassell
Journal:  Oncogene       Date:  1993-11       Impact factor: 9.867

7.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

8.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

Authors:  C Gillett; V Fantl; R Smith; C Fisher; J Bartek; C Dickson; D Barnes; G Peters
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

9.  Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation.

Authors:  Sachin K Deshmukh; Sanjeev K Srivastava; Arun Bhardwaj; Ajay P Singh; Nikhil Tyagi; Saravanakumar Marimuthu; Donna L Dyess; Valeria Dal Zotto; James E Carter; Seema Singh
Journal:  Oncotarget       Date:  2015-05-10

10.  Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis.

Authors:  Zhong-Yu Yuan; Ting Dai; Shu-Sen Wang; Rou-Jun Peng; Xing-Hua Li; Tao Qin; Li-Bing Song; Xi Wang
Journal:  Onco Targets Ther       Date:  2014-09-26       Impact factor: 4.147

View more
  12 in total

1.  [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells in vitro].

Authors:  Chen Xiaohui; L I Xin; W U Dehua
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-08-30

2.  Reliable epithelial-mesenchymal transition biomarkers for colorectal cancer detection.

Authors:  Kaitlin A Goettsch; Ling Zhang; Amar B Singh; Punita Dhawan; Dhundy K Bastola
Journal:  Biomark Med       Date:  2022-07-27       Impact factor: 2.498

3.  ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control.

Authors:  Joanna DeSalvo; Yuguang Ban; Luyuan Li; Xiaodian Sun; Zhijie Jiang; Darcy A Kerr; Mahsa Khanlari; Maria Boulina; Mario R Capecchi; Juha M Partanen; Lin Chen; Tadashi Kondo; David M Ornitz; Jonathan C Trent; Josiane E Eid
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

4.  ETV4: an emerging target in pancreatic cancer.

Authors:  Sachin Kumar Deshmukh; Ajay P Singh; Seema Singh
Journal:  Oncoscience       Date:  2018-10-11

5.  Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer.

Authors:  Toyoharu Kamibeppu; Koji Yamasaki; Kozue Nakahara; Takahiro Nagai; Naoki Terada; Hiromasa Tsukino; Shoichiro Mukai; Toshiyuki Kamoto
Journal:  Res Rep Urol       Date:  2018-10-03

6.  Knockdown of P3H4 inhibits proliferation and invasion of bladder cancer.

Authors:  Lin Hao; Kun Pang; Hui Pang; Junjie Zhang; Zhiguo Zhang; Houguang He; Rongsheng Zhou; Zhenduo Shi; Conghui Han
Journal:  Aging (Albany NY)       Date:  2020-02-04       Impact factor: 5.682

7.  Roquin1 inhibits the proliferation of breast cancer cells by inducing G1/S cell cycle arrest via selectively destabilizing the mRNAs of cell cycle-promoting genes.

Authors:  Wenbao Lu; Meicen Zhou; Bing Wang; Xueting Liu; Bingwei Li
Journal:  J Exp Clin Cancer Res       Date:  2020-11-23

8.  Circular RNA hsa_circ_0001666 sponges miR‑330‑5p, miR‑193a‑5p and miR‑326, and promotes papillary thyroid carcinoma progression via upregulation of ETV4.

Authors:  Ying Qi; Jingni He; Ying Zhang; Lidong Wang; Yifan Yu; Baiyu Yao; Zhong Tian
Journal:  Oncol Rep       Date:  2021-03-24       Impact factor: 3.906

9.  Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1.

Authors:  Xiahui Li; Shujing Li; Bowen Li; Yanan Li; Sattout Aman; Kangkai Xia; Yuxi Yang; Bashir Ahmad; Huijian Wu
Journal:  NPJ Precis Oncol       Date:  2021-03-19

10.  Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies.

Authors:  Leonie K de Klerk; Ruben S A Goedegebuure; Adam J Bass; Sarah Derks; Nicole C T van Grieken; Johanna W van Sandick; Annemieke Cats; Jurrien Stiekema; Rosa T van der Kaaij; Arantza Farina Sarasqueta; Manon van Engeland; Maarten A J M Jacobs; Roy L J van Wanrooij; Donald L van der Peet; Aaron R Thorner; Henk M W Verheul; Victor L J L Thijssen
Journal:  Mol Oncol       Date:  2021-02-23       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.